Multiple studies confirm this
In this post, well explore both delivery routes in detail, reviewing the pros, cons, mechanisms, and best-use cases for each formso you can make an informed decision about which may be right for you
Less Common Side Effects These are not experienced by most people but are possible
These are absolute contraindications
What Happens Next The immediate milestone in the CagriSema FDA review is the PDUFA action date, expected in the fourth quarter of 2026
First, the compliance clock on FDORA's Diversity Action Plan mandate has effectively stalled: the statutory deadline for final guidance passed in June 2025 without FDA publishing it ( [9] ), following a politically charged episode in which the guidance was removed from FDA's website under a DEI-related executive order and then restored by court order ( [7] ) ( [8] )